全文获取类型
收费全文 | 340篇 |
免费 | 17篇 |
出版年
2021年 | 6篇 |
2020年 | 9篇 |
2019年 | 2篇 |
2018年 | 8篇 |
2017年 | 4篇 |
2016年 | 7篇 |
2015年 | 19篇 |
2014年 | 11篇 |
2013年 | 22篇 |
2012年 | 12篇 |
2011年 | 12篇 |
2010年 | 10篇 |
2009年 | 5篇 |
2008年 | 16篇 |
2007年 | 11篇 |
2006年 | 8篇 |
2005年 | 12篇 |
2004年 | 8篇 |
2003年 | 14篇 |
2002年 | 15篇 |
2001年 | 11篇 |
2000年 | 9篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 4篇 |
1995年 | 4篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 7篇 |
1988年 | 9篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1980年 | 2篇 |
1973年 | 2篇 |
1971年 | 3篇 |
1969年 | 8篇 |
1968年 | 4篇 |
1967年 | 4篇 |
1954年 | 1篇 |
1942年 | 1篇 |
1940年 | 2篇 |
1938年 | 2篇 |
1933年 | 1篇 |
1853年 | 3篇 |
1851年 | 4篇 |
排序方式: 共有357条查询结果,搜索用时 15 毫秒
121.
122.
Dominique?P?GermainEmail author Roberto?Giugliani Derralynn?A?Hughes Atul?Mehta Kathy?Nicholls Laura?Barisoni Charles?J?Jennette Alexander?Bragat Jeff?Castelli Sheela?Sitaraman David?J?Lockhart Pol?F?Boudes 《Orphanet journal of rare diseases》2012,7(1):91
Background
Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. We report on the safety and pharmacodynamics of migalastat hydrochloride, an investigational pharmacological chaperone given orally at 150 mg every-other-day.Methods
Two open-label uncontrolled phase 2 studies of 12 and 24 weeks (NCT00283959 and NCT00283933) in 9 males with FD were combined. At multiple time points, α-Gal A activity and GL-3 levels were quantified in blood cells, kidney and skin. GL-3 levels were also evaluated through skin and renal histology.Results
Compared to baseline, increased α-Gal A activity of at least 50% was demonstrated in blood, skin and kidney in 6 of 9 patients. Patients’ increased α-Gal A activities paralleled the α-Gal A increases observed in vitro in HEK-293 cells transfected with the corresponding mutant form of the enzyme. The same 6 patients who demonstrated increases of α-Gal A activity also had GL-3 reduction in skin, urine and/or kidney, and had α-Gal A mutations that responded in transfected cells incubated with the drug. The 3 patients who did not show a consistent response in vivo had α-Gal A mutations that did not respond to migalastat HCl in transfected cells. Migalastat HCl was well tolerated.Conclusions
Migalastat HCl is a candidate pharmacological chaperone that provides a novel genotype-specific treatment for FD. It enhanced α-Gal A activity and resulted in GL-3 substrate decrease in patients with responsive GLA mutations. Phase 3 studies are ongoing.Trial registration
Clinicaltrial.gov: NCT00283959 and NCT00283933123.
Ann M. Bayly Janette M. Berglez Onisha Patel Laura A. Castelli Eleanor G. Hankins Peter Coloe Carol Hopkins Sibley Ian G. Macreadie 《FEMS microbiology letters》2001,204(2):387-390
Saccharomyces cerevisiae mutants deficient in folate synthesis have been constructed and employed to study the utilisation of exogenous folates in yeast. One mutant specifically lacked dihydropteroate synthase while the second lacked dihydrofolate synthase. Exogenous folinic acid restored optimal growth to both strains. Folic acid did not generally rescue growth but spontaneous isolates capable of utilising folic acid were selected. The folic acid synthesis pathway in the folate utilising isolates was restored via transformation with FOL1 or FOL3 expression plasmids and transformants were tested for resistance to sulfamethoxazole (SMX). The presence of elevated levels of folic acid led to greatly reduced SMX sensitivity regardless of whether strains were folate utilisers or not. 相似文献
124.
Foschi FG Gramenzi A Castelli E Cursaro C Pagani S Margotti M D'Errico A Andreone P Stefanini GF Bernardi M 《Cytokine》2000,12(6):815-818
In the present study, high levels of CD30s, a glycoprotein preferentially expressed and released by T lymphocytes producing Th(2)-type cytokines, were seen in the sera of patients with chronic hepatitis C, and a correlation with histological activity of the disease was found. CD30s levels were assayed in the sera of 29 HCV RNA-positive patients with histologically proven chronic active hepatitis and in 30 healthy blood donors. Thirteen of 29 (45%) HCV patients had CD30s serum levels above the normal range (>20 U/ml). Mean CD30s serum levels were significantly higher in HCV patients than in controls (P<0.0005). A positive correlation was found between serum CD30s levels and both the histological activity index (r=0.59, P=0.001) and ALT serum levels (r=0.5; P=0.006). The raised CD30s level found in more severe HCV liver disease indirectly suggests activation and expansion of Th(2)cells. CD30s levels could represent a useful surrogate marker of activity in chronic HCV infections. 相似文献
125.
De Filippo A Binder RJ Camisaschi C Beretta V Arienti F Villa A Della Mina P Parmiani G Rivoltini L Castelli C 《Journal of immunology (Baltimore, Md. : 1950)》2008,181(9):6525-6535
Glucose-regulated stress protein gp96 is known to be involved in the host response to pathogens and to cancer. Our study explored the relationships between gp96 and human blood plasmacytoid dendritic cells (pDC) and proved that gp96 directly targets pDC by a receptor-dependent interaction. Competition studies identified CD91 as a gp96 receptor on pDC, and laser confocal imaging indicated that CD91 triggering was followed by gp96 endocytosis and trafficking into early endosomes and later into the endoplasmic reticulum compartment. Using two alternative Abs, we showed that human blood pDC reproducibly expressed CD91, although different levels of expression were detectable among the analyzed donors. Moreover, CpG-matured pDC displayed CD91 receptor up-regulation that correlated with an increased gp96 binding. Functionally, gp96-pDC interaction activated the NF-kappaB pathway, leading to the nuclear translocation of the NF-kappaB complex. gp96-treated pDC maintained an immature phenotype, while they down-modulated the release of IL-8, suggesting an anti-inflammatory role of this pathway, and they strongly up-regulated the cell surface expression of the gp96 receptor CD91. CpG-matured or gp96-treated pDC, expressing high levels of the gp96 receptor CD91, antagonized the gp96-induced activation of monocyte-derived dendritic cells in terms of cell surface phenotype and cytokine production. Altogether, these results suggest that gp96-pDC interaction might represent an active mechanism controlling the strength of the immune response to free, extracellular available gp96; this mechanism could be particularly relevant in wounds and chronic inflammation. 相似文献
126.
127.
128.
Iseli TJ Oakhill JS Bailey MF Wee S Walter M van Denderen BJ Castelli LA Katsis F Witters LA Stapleton D Macaulay SL Michell BJ Kemp BE 《The Journal of biological chemistry》2008,283(8):4799-4807
AMP-activated protein kinase (AMPK) plays multiple roles in the body's overall metabolic balance and response to exercise, nutritional stress, hormonal stimulation, and the glucose-lowering drugs metformin and rosiglitazone. AMPK consists of a catalytic alpha subunit and two non-catalytic subunits, beta and gamma, each with multiple isoforms that form active 1:1:1 heterotrimers. Here we show that recombinant human AMPK alpha1beta1gamma1 expressed in insect cells is monomeric and displays specific activity and AMP responsiveness similar to rat liver AMPK. The previously determined crystal structure of the core of mammalian alphabetagamma complex shows that beta binds alpha and gamma. Here we show that a beta1(186-270)gamma1 complex can form in the absence of detectable alpha subunit. Moreover, using alanine mutagenesis we show that beta1 Thr-263 and Tyr-267 are required for betagamma association but not alphabeta association. 相似文献
129.
Zaragoza O Chrisman CJ Castelli MV Frases S Cuenca-Estrella M Rodríguez-Tudela JL Casadevall A 《Cellular microbiology》2008,10(10):2043-2057
Cryptococcus neoformans is a facultative intracellular pathogen. The most distinctive feature of C. neoformans is a polysaccharide capsule that enlarges depending on environmental stimuli. The mechanism by which C. neoformans avoids killing during phagocytosis is unknown. We hypothesized that capsule growth conferred resistance to microbicidal molecules produced by the host during infection, particularly during phagocytosis. We observed that capsule enlargement conferred resistance to reactive oxygen species produced by H(2)O(2) that was not associated with a higher catalase activity, suggesting a new function for the capsule as a scavenger of reactive oxidative intermediates. Soluble capsular polysaccharide protected C. neoformans and Saccharomyces cerevisiae from killing by H(2)O(2). Acapsular mutants had higher susceptibility to free radicals. Capsular polysaccharide acted as an antioxidant in the nitroblue tetrazolium (NBT) reduction coupled to beta-nicotinamide adenine dinucleotide (NADH)/phenazine methosulfate (PMS) assay. Capsule enlargement conferred resistance to antimicrobial peptides and the antifungal drug Amphotericin B. Interestingly, the capsule had no effect on susceptibility to azoles and increased susceptibility to fluconazole. Capsule enlargement reduced phagocytosis by environmental predators, although we also noticed that in this system, starvation of C. neoformans cells produced resistance to phagocytosis. Our results suggest that capsular enlargement is a mechanism that enhances C. neoformans survival when ingested by phagocytic cells. 相似文献
130.
Basilico N Bosisio E Buelli F Campiani G Casagrande M Castelli F Coghi P Corbett Y Cortelezzi L D'Alessandro S Dell'Agli M Esposito F Fattorusso C Fattorusso E Finaurini S Galli GV Gemma S Habluetzel A Lucantoni L Melato S Monti D Olliaro P Omodeo-Salè F Parapini S Persico M Rizzi M Romeo S Rossi F Rusconi C Sparatore A Scafati OT van den Bogaart E Taramelli D Vaiana N Yerbanga S 《Parassitologia》2008,50(1-2):133-136
Clinical treatment-failures to affordable drugs encouraged new investigation for discovery and development of new prophylactic and therapeutic interventions against malaria. The Drug Discovery Cluster (DDcl) of the Italian Malaria Network gathers several highly integrated and complementary laboratories from different Italian Institutions to identify, synthesise, screen in vitro and in vivo new antimalarial molecules directed against the intraerythrocytic stage of P. falciparum parasites and/or with transmission blocking activity to select lead compounds for further development. Complementary research activities, both in vitro and in the clinics, aim at investigating the pathogenetic mechanisms of severe malaria anaemia and the different manifestations of the disease in malaria-HIV co-infected patients to identify new therapies and improve survival. 相似文献